Corrigendum to “Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study” [Gynecol. Oncol. 151 (2018) 18–23]

Advanced Stage ◽

Oncology Group ◽

Oncology Group Study ◽

Dose Modification ◽

Chemotherapy Dose

Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2018.07.021 ◽

2018 ◽

Vol 151 (1) ◽

pp. 18-23 ◽

Cited By ~ 5

Author(s):

Alexander B. Olawaiye ◽

James J. Java ◽

Thomas C. Krivak ◽

Michael Friedlander ◽

David G. Mutch ◽

...

Keyword(s):

Ovarian Cancer ◽

Adjuvant Chemotherapy ◽

Gynecologic Oncology ◽

Advanced Stage ◽

Oncology Group ◽

Oncology Group Study ◽

Dose Modification ◽

Chemotherapy Dose

Does maintaining adjuvant chemotherapy dose intensity have an impact on the outcome of treatment in ovarian cancer patients?: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2011.12.058 ◽

2012 ◽

Vol 125 ◽

pp. S25

Author(s):

A. Olawaiye ◽

J. Java ◽

T. Krivak ◽

M. Bookman ◽

T. Herzog

Keyword(s):

Ovarian Cancer ◽

Adjuvant Chemotherapy ◽

Cancer Patients ◽

Gynecologic Oncology ◽

Dose Intensity ◽

Oncology Group ◽

Oncology Group Study ◽

Chemotherapy Dose ◽

Chemotherapy Dose Intensity

Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708)

BMC Cancer ◽

10.1186/s12885-019-5514-7 ◽

2019 ◽

Vol 19 (1) ◽

Cited By ~ 4

Author(s):

Young Shin Chung ◽

Sang-Yoon Park ◽

Jung-Yun Lee ◽

Jeong-Yeol Park ◽

Jeong-Won Lee ◽

...

Keyword(s):

Ovarian Cancer ◽

Neoadjuvant Chemotherapy ◽

Gynecologic Oncology ◽

Serous Carcinoma ◽

High Grade ◽

Advanced Stage ◽

Oncology Group ◽

Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: A gynecologic oncology group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2012.01.008 ◽

2012 ◽

Vol 125 (2) ◽

pp. 421-426 ◽

Cited By ~ 32

Author(s):

Jennifer M. Rubatt ◽

Kathleen M. Darcy ◽

Chunqiao Tian ◽

Franco Muggia ◽

Rajiv Dhir ◽

...

Keyword(s):

Ovarian Cancer ◽

Clinical Outcomes ◽

Gynecologic Oncology ◽

Advanced Stage ◽

Oncology Group ◽

Oncology Group Study ◽

Pre Treatment ◽

Tumor Expression

The association between quality of life domains and overall survival in ovarian cancer patients during adjuvant chemotherapy: A Gynecologic Oncology Group Study

Gynecologic Oncology ◽

10.1016/j.ygyno.2011.11.032 ◽

2012 ◽

Vol 124 (3) ◽

pp. 379-382 ◽

Cited By ~ 32

Author(s):

Vivian E. von Gruenigen ◽

Helen Q. Huang ◽

Karen M. Gil ◽

Heidi E. Frasure ◽

Deborah K. Armstrong ◽

...

Keyword(s):

Quality Of Life ◽

Ovarian Cancer ◽

Overall Survival ◽

Adjuvant Chemotherapy ◽

Gynecologic Oncology ◽

Life Domains ◽

Oncology Group ◽

A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D

Journal of Gynecologic Oncology ◽

10.3802/jgo.2019.30.e112 ◽

2019 ◽

Vol 30 (6) ◽

Cited By ~ 2

Author(s):

Jung-Yun Lee ◽

Jae Weon Kim ◽

Myong Cheol Lim ◽

Sunghoon Kim ◽

Hee Seung Kim ◽

...

Keyword(s):

Ovarian Cancer ◽

Neoadjuvant Chemotherapy ◽

Phase Ii ◽

Phase Ii Study ◽

Gynecologic Oncology ◽

Advanced Stage ◽

Oncology Group ◽

Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2021.11.013 ◽

2021 ◽

Author(s):

Nefertiti C. duPont ◽

Danielle Enserro ◽

Mark F. Brady ◽

Katherine Moxley ◽

Joan L. Walker ◽

...

Keyword(s):

Ovarian Cancer ◽

Gynecologic Oncology ◽

Prognostic Significance ◽

Advanced Stage ◽

Oncology Group ◽

Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2011.11.022 ◽

2012 ◽

Vol 124 (3) ◽

pp. 575-581 ◽

Cited By ~ 56

Author(s):

Chunqiao Tian ◽

Christine B. Ambrosone ◽

Kathleen M. Darcy ◽

Thomas C. Krivak ◽

Deborah K. Armstrong ◽

...

Keyword(s):

Ovarian Cancer ◽

Clinical Outcomes ◽

Gynecologic Oncology ◽

Advanced Stage ◽

Common Variants ◽

Oncology Group ◽

Association between the N-terminally truncated (ΔN) p63α (ΔNp63α) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2009.07.035 ◽

2009 ◽

Vol 115 (3) ◽

pp. 424-429 ◽

Cited By ~ 3

Author(s):

Elizabeth L. Jewell ◽

Kathleen M. Darcy ◽

Alan Hutson ◽

Paula S. Lee ◽

Laura J. Havrilesky ◽

...

Keyword(s):

Ovarian Cancer ◽

Gynecologic Oncology ◽

Progression Free Survival ◽

Advanced Stage ◽

Oncology Group ◽

Vegf Expression ◽

Free Survival ◽

Loss of p16 in advanced stage epithelial ovarian cancer is associated with chemoresistant disease, suboptimal debulking and poor progression-free survival: A Gynecologic Oncology Group study.

Gynecologic Oncology ◽

10.1016/j.ygyno.2011.12.084 ◽

2012 ◽

Vol 125 ◽

pp. S37

Author(s):

A. Wallace ◽

K. Darcy ◽

A. Alvarez-Secord ◽

A. Hutson ◽

D. Tritchler ◽

...

Keyword(s):

Ovarian Cancer ◽

Gynecologic Oncology ◽

Progression Free Survival ◽

Advanced Stage ◽

Oncology Group ◽

Free Survival ◽